Differences in P-glycoprotein-170 expression and activity between Crohn’s disease and ulcerative colitis

Yacyshyn, Bruce; Maksymowych, Walter P.; Bowen-Yacyshyn, Mary Beth

doi:10.1016/s0198-8859(99)00036-1

Cited by 41 publications

(32 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to Englund et al, individuals with active UC have been shown to exhibit lower P-gp levels in the colon [19]. Yacyshyn et al observed not only a decreased mRNA level for the ABCB1/MDR1 gene, but also lower P-gp activity in the lymphocyte population deriving from the intestinal mucosa of patients with active UC [20]. The polymorphism of the ABCB1/MDR1 gene at position 1236 is one …”

Section: Discussionmentioning

confidence: 99%

The importance of C1236T polymorphism in the ABCB1/MDR1 gene in assessment of susceptibility to inflammatory bowel diseases in the Polish population

Dudarewicz¹,

Barańska²,

Rychlik‐Sych³

et al. 2013

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

The importance of C1236T polymorphism in the ABCB1/MDR1 gene in assessment of susceptibility to inflammatory bowel diseases in the Polish population

Dudarewicz¹,

Barańska²,

Rychlik‐Sych³

et al. 2013

View full text Add to dashboard Cite

“…The multidrug resistance (MDR) gene coding for a drug efflux pump P-glycoprotein 170(Pgp-170) expressed on the surface of lymphocytes and intestinal epithelial cells [38,39] . In this study, Pgp-170 was elevated significantly in blood and tissues of refractory UC patients.…”

Section: Discussionmentioning

confidence: 99%

“…Poor response to medical therapy of certain UC patients might be related to MDR expression because glucocorticoids are known Pgp-170 substrates. There was no difference of Pgp-170 in tissues and blood, indicating that peripheral blood lymphocyte (PBL) MDR remained stable over time and was not influenced by disease activity or glucocorticoid therapy, both PBL and mucosal MDR expression appeared independent of disease activity, and there was a significant correlation between PBL and MDR expression and intestinal epithelial lymphocyte and epithelial cell expression [38,39] . After treatment with Kangshuangling sublingual tablets, Pgp-170 dropped significantly in both blood and tissues, indicating that Kangshuangling sublingual tablet could inhibit the expression of MDR, but Pgp-170 was still higher than that of the normal controls, indicating that PBL and mucosal MDR may play an important role in determining the response of refractory UC patients to glucocorticoid therapy.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Different therapy for different types of ulcerative colitis in China

Jiang

Cui²

2004

WJG

View full text Add to dashboard Cite

AIM:To study the different therapy for different types of ulcerative colitis (UC) in China. METHODS:Among 102 UC patients, 42 chronic relapse type UC patients were randomly divided into olsalazine sodium treatment group (n=21) and SASP group (n=21). Clinical effects and safety were observed in the 2 groups. Forty-two first episode type UC patients were randomly divided into Heartleaf houttuynia herb treatment group (n=21) and SASP group (n=21). Clinical effects were observed in the 2 groups while ultrastructure of colonic mucosa, ICAM-1 and the pressure of distant colon were studied in Heartleaf houttuynia herb group. Eighteen patients (8 males, 10 females) with refractory UC and unresponsive to high-dose prednisolone and sulfasalazine therapy more than one month were treated with Kangshuanling (7 200 U/d). Prednisolone was gradually stopped and sulfasalazine was maintained. Stool frequency, rectal bleeding, colonoscopy, general well-being, histology were observed and CD62p, CD63, CD54, Pgp-170 (flow cytometry), TXA2 (RIA), blood platelet aggregation rate and thrombosis length in vitro were assessed. RESULTS:In the 42 chronic relapse type UC patients, the overall clinical effects of olsalazine sodium group (complete remission in 16, improvement in 4, inefficiency in 1) were better than those of SASP group (complete remission in 10, improvement in 4, inefficiency in 7, P<0.05). Symptomatic remission of olsalazine sodium group (complete remission in 15, partial remission in 5, inefficiency in 1) was better than that of SASP group (complete remission in 10, partial remission in 5, inefficiency in 6, P<0.05). The colonoscopic remission of olsalazine sodium group(complete remission in 11, partial remission in 9, inefficiency in 1) was better than that of SASP group (complete remission in 7, partial remission in 8, inefficiency in 6, P<0.05). The histologic remission of olsalazine sodium group (complete remission in 13, partial remission in 7, inefficiency in in 1) was better than that of SASP group (complete remission in 6, partial remission in 10, inefficiency in 5, P<0.05). The side effects of gastrointestinal tract in olsalazine sodium group were less than those of SASP group except for frequency of watery diarrhea. No other side effects were observed in olsalazine sodium group while ALT increase, WBC decrease and skin eruption were observed in SASP group. Two patients relapsed in olsalazine sodium group while 8 cases relapsed in SASP group during the flow-up period (from six months to one year). In the 42 first episode type UC patients, the clinical effect of Heartleaf houttuynia herb group (complete remission in 20, 95.2%; improvement in 1, 4.8%) was better than that of SASP group (complete remission in 15, 72.4%, improvement in 5, 23.8%; inefficiency in 1, 3.8%, P<0.01). The time of stool frequency recovering to normal (5.6±3.3 d), and blood stool disappearance (6.7±3.8 d) and abdominal pain disappearance (6.1±3.5 d) in Heartleaf houttuynia herb group was all shorter than that in SASP group (9.5±4.9 d,...

show abstract

“…Gemeinsame Folgeerscheinungen sind Therapieversagen, Indikation zur chirurgischen Intervention (bei Darmerkrankungen) und schlechterer Krankheitsverlauf. Eine Analyse der P-gp-Expression in CD8-positiven intestinalen Lymphozyten wies deutliche Unterschiede zwischen Morbus Crohn und Colitis ulcerosa auf, mit denen man das Therapieversagen von Ciclosporin A bei M. Crohn erklären könnte[69].Die Diskussionen zur pathogenetischen Bedeutung von P-gp bei AlzheimerDemenz und Herzinsuffizienz sind dagegen noch sehr spekulativ.Bisher weiß man lediglich, dass β-Amyloid mittels P-gp durch Zellmembranen transportiert werden kann [35] und Personen mit geringem P-gp-Gehalt in bestimmten Hirnregionen ein höheres Risiko für Amyloidablagerung haben[65].Bei dilatativer Kardiomyopathie wird in den Endothelzellen der myokardialen Kapillaren signifikant weniger P-gp als in gesunden Herzen exprimiert[39].Welche klinische Bedeutung diese Befunde für die Pathogenese des M.Alzheimer bzw.für die Therapie und Prognose der Herzinsuffizienz haben,müssen weitere Untersuchungen zeigen. Unterstützt wurden die Befunde durch Rhodamin-123-Efflux-Bestimmungen an CD56-positiven "natural killer cells".Abb.…”

unclassified

Arzneimitteltransporter

Siegmund

Cascorbi

2003

Internist

View full text Add to dashboard Cite

Das MDR1-Genprodukt P-Glykoprotein ist nicht nur Ursache der "multidrug resistance", sondern erfüllt auch eine wichtige physiologische Funk-tion, da es in zahlreichen Gewebe-und Organschranken sowie in Zellen mit Ausscheidungsfunktion vorkommt. Es behindert die Absorption und Verteilung einer Vielzahl von Arzneistoffen und fördert ihre Elimination. Die Variabilität der Expression und Funktion von P-Glykoprotein kann sich auf die Sicherheit der Arzneimitteltherapie auswirken. Faktoren, die zu klinisch bedeutsamen Verände-rungen führen können, sind

show abstract

Differences in P-glycoprotein-170 expression and activity between Crohn’s disease and ulcerative colitis

Cited by 41 publications

References 23 publications

The importance of C1236T polymorphism in the ABCB1/MDR1 gene in assessment of susceptibility to inflammatory bowel diseases in the Polish population

The importance of C1236T polymorphism in the ABCB1/MDR1 gene in assessment of susceptibility to inflammatory bowel diseases in the Polish population

Different therapy for different types of ulcerative colitis in China

Arzneimitteltransporter

Contact Info

Product

Resources

About